FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115399503> ?p ?o ?g. }

• W2115399503 endingPage "1609" @default.
• W2115399503 startingPage "1598" @default.
• W2115399503 abstract "Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is arduous and uptake is low, but new highly effective and tolerable interferon-free direct-acting antiviral (DAA) treatments could facilitate increased uptake. We projected the potential impact of DAA treatments on PWID HCV prevalence in three settings. A dynamic HCV transmission model was parameterized to three chronic HCV prevalence settings: Edinburgh, UK (25%); Melbourne, Australia (50%); and Vancouver, Canada (65%). Using realistic scenarios of future DAAs (90% sustained viral response, 12 weeks duration, available 2015), we projected the treatment rates required to reduce chronic HCV prevalence by half or three-quarters within 15 years. Current HCV treatment rates may have a minimal impact on prevalence in Melbourne and Vancouver (<2% relative reductions) but could reduce prevalence by 26% in 15 years in Edinburgh. Prevalence could halve within 15 years with treatment scale-up to 15, 40, or 76 per 1,000 PWID annually in Edinburgh, Melbourne, or Vancouver, respectively (2-, 13-, and 15-fold increases, respectively). Scale-up to 22, 54, or 98 per 1,000 PWID annually could reduce prevalence by three-quarters within 15 years. Less impact occurs with delayed scale-up, higher baseline prevalence, or shorter average injecting duration. Results are insensitive to risk heterogeneity or restricting treatment to PWID on OST. At existing HCV drug costs, halving chronic prevalence would require annual treatment budgets of US $3.2 million in Edinburgh and approximately $50 million in Melbourne and Vancouver. Conclusion: Interferon-free DAAs could enable increased HCV treatment uptake among PWID, which could have a major preventative impact. However, treatment costs may limit scale-up, and should be addressed. (Hepatology 2013;58:1598–1609)" @default.
• W2115399503 created "2016-06-24" @default.
• W2115399503 creator A5000073653 @default.
• W2115399503 creator A5002616190 @default.
• W2115399503 creator A5004545282 @default.
• W2115399503 creator A5004579061 @default.
• W2115399503 creator A5013176250 @default.
• W2115399503 creator A5036570109 @default.
• W2115399503 creator A5044801510 @default.
• W2115399503 creator A5045529959 @default.
• W2115399503 creator A5052909853 @default.
• W2115399503 creator A5065033982 @default.
• W2115399503 creator A5069135365 @default.
• W2115399503 date "2013-08-26" @default.
• W2115399503 modified "2023-10-17" @default.
• W2115399503 title "Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals" @default.
• W2115399503 cites W1895949411 @default.
• W2115399503 cites W1932141100 @default.
• W2115399503 cites W1965862609 @default.
• W2115399503 cites W1977821291 @default.
• W2115399503 cites W1978701515 @default.
• W2115399503 cites W1979129700 @default.
• W2115399503 cites W1979778220 @default.
• W2115399503 cites W1980760254 @default.
• W2115399503 cites W1985982900 @default.
• W2115399503 cites W1987858307 @default.
• W2115399503 cites W1993074481 @default.
• W2115399503 cites W1995021702 @default.
• W2115399503 cites W2000926720 @default.
• W2115399503 cites W2001997653 @default.
• W2115399503 cites W2002495622 @default.
• W2115399503 cites W2011437704 @default.
• W2115399503 cites W2014963784 @default.
• W2115399503 cites W2022031150 @default.
• W2115399503 cites W2022967348 @default.
• W2115399503 cites W2023899169 @default.
• W2115399503 cites W2027792646 @default.
• W2115399503 cites W2047400589 @default.
• W2115399503 cites W2062573578 @default.
• W2115399503 cites W2074949286 @default.
• W2115399503 cites W2075641004 @default.
• W2115399503 cites W2077095964 @default.
• W2115399503 cites W2088295272 @default.
• W2115399503 cites W2089033703 @default.
• W2115399503 cites W2093150448 @default.
• W2115399503 cites W2101368910 @default.
• W2115399503 cites W2104563699 @default.
• W2115399503 cites W2106791445 @default.
• W2115399503 cites W2110957526 @default.
• W2115399503 cites W2114473223 @default.
• W2115399503 cites W2117147397 @default.
• W2115399503 cites W2125963799 @default.
• W2115399503 cites W2126506419 @default.
• W2115399503 cites W2127291044 @default.
• W2115399503 cites W2131792659 @default.
• W2115399503 cites W2135630746 @default.
• W2115399503 cites W2138053911 @default.
• W2115399503 cites W2142165617 @default.
• W2115399503 cites W2143559032 @default.
• W2115399503 cites W2143929325 @default.
• W2115399503 cites W2152505869 @default.
• W2115399503 cites W2157811865 @default.
• W2115399503 cites W2158806421 @default.
• W2115399503 cites W2164227241 @default.
• W2115399503 cites W2169923344 @default.
• W2115399503 cites W2222306685 @default.
• W2115399503 cites W2314461521 @default.
• W2115399503 doi "https://doi.org/10.1002/hep.26431" @default.
• W2115399503 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3933734" @default.
• W2115399503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23553643" @default.
• W2115399503 hasPublicationYear "2013" @default.
• W2115399503 type Work @default.
• W2115399503 sameAs 2115399503 @default.
• W2115399503 citedByCount "434" @default.
• W2115399503 countsByYear W21153995032013 @default.
• W2115399503 countsByYear W21153995032014 @default.
• W2115399503 countsByYear W21153995032015 @default.
• W2115399503 countsByYear W21153995032016 @default.
• W2115399503 countsByYear W21153995032017 @default.
• W2115399503 countsByYear W21153995032018 @default.
• W2115399503 countsByYear W21153995032019 @default.
• W2115399503 countsByYear W21153995032020 @default.
• W2115399503 countsByYear W21153995032021 @default.
• W2115399503 countsByYear W21153995032022 @default.
• W2115399503 countsByYear W21153995032023 @default.
• W2115399503 crossrefType "journal-article" @default.
• W2115399503 hasAuthorship W2115399503A5000073653 @default.
• W2115399503 hasAuthorship W2115399503A5002616190 @default.
• W2115399503 hasAuthorship W2115399503A5004545282 @default.
• W2115399503 hasAuthorship W2115399503A5004579061 @default.
• W2115399503 hasAuthorship W2115399503A5013176250 @default.
• W2115399503 hasAuthorship W2115399503A5036570109 @default.
• W2115399503 hasAuthorship W2115399503A5044801510 @default.
• W2115399503 hasAuthorship W2115399503A5045529959 @default.
• W2115399503 hasAuthorship W2115399503A5052909853 @default.
• W2115399503 hasAuthorship W2115399503A5065033982 @default.
• W2115399503 hasAuthorship W2115399503A5069135365 @default.
• W2115399503 hasBestOaLocation W21153995032 @default.

• next